22 results
SC TO-T/A
EX-99
Concentra Merger Sub II, Inc.
14 Feb 24
Third party tender offer statement (amended)
10:35am
for the treatment of non-small cell lung cancer, (b) the Company’s next-generation BCR-ABL program focused on relapsed/refractory chronic myeloid
SC TO-T/A
EX-99
THRX
Theseus Pharmaceuticals Inc
30 Jan 24
Third party tender offer statement (amended)
8:23am
for the treatment of non-small cell lung cancer, (b) Theseus’ next-generation BCR-ABL program focused on relapsed/refractory chronic myeloid leukemia … of non-small cell lung cancer, (b) Theseus’ next-generation BCR-ABL program focused on relapsed/refractory chronic myeloid leukemia and Philadelphia
SC 14D9
THRX
Theseus Pharmaceuticals Inc
10 Jan 24
Tender offer solicitation
9:47am
focused on relapsed/refractory chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia or (C) Theseus’ KIT inhibitor
SC TO-T
EX-99
THRX
Theseus Pharmaceuticals Inc
10 Jan 24
Third party tender offer statement
8:51am
program focused on relapsed/refractory chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia, or (c) Theseus … cancer, (b) Theseus’ next-generation BCR-ABL program focused on relapsed/refractory chronic myeloid leukemia and Philadelphia chromosome-positive acute
SC14D9C
EX-99.1
THRX
Theseus Pharmaceuticals Inc
22 Dec 23
Written communication relating to third party tender offer
6:52am
for the treatment of relapsed/refractory chronic myeloid leukemia and newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia
8-K
EX-2.1
bvljnqczz5
22 Dec 23
Entry into a Material Definitive Agreement
6:36am
8-K
EX-99.1
h4bt30dv
22 Dec 23
Entry into a Material Definitive Agreement
6:36am
8-K
v41vgbib
22 Dec 23
Entry into a Material Definitive Agreement
6:36am
8-K
EX-99.1
kxf27lhk
13 Nov 23
Theseus Pharmaceuticals Announces Process to Explore Strategic Alternatives
4:06pm
8-K
EX-99.1
4pg1cslk
10 Aug 23
Theseus Pharmaceuticals Announces Business Highlights and Reports Second Quarter 2023 Financial Results
7:05am
8-K
EX-99.1
w0oop7
13 Jul 23
Theseus Pharmaceuticals to Discontinue Enrollment in Phase 1/2 Study and Terminate Development of THE-630 in Patients with GIST
4:08pm
8-K
EX-99.1
fi1ms9n4uftn wu4i
25 May 23
Theseus Pharmaceuticals Reports Initial Dose Escalation Data from Ongoing Phase 1/2 Trial of THE-630 in Patients with Advanced GIST
5:04pm
8-K
EX-99.2
rzciuattj998g pc
25 May 23
Theseus Pharmaceuticals Reports Initial Dose Escalation Data from Ongoing Phase 1/2 Trial of THE-630 in Patients with Advanced GIST
5:04pm
8-K
EX-99.1
x0t0u7ip8
11 May 23
Theseus Pharmaceuticals Announces Business Highlights and Reports First Quarter 2023 Financial Results
7:09am
424B4
9evxaifb32yi6piz
7 Oct 21
Prospectus supplement with pricing info
5:03pm
S-1/A
ad4uha hubi1
30 Sep 21
IPO registration (amended)
6:33am
S-1
948ww9ox1jvjmjei5si
15 Sep 21
IPO registration
4:04pm